Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > FDA guides on how AA can be converted to full approval.

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Mar 25, 2023 2:13pm

158 Views

Post# 35360424

RE:RE:RE:RE:RE:RE:RE:FDA guides on how AA can be converted to full approval.

If If's and but's were candies and nuts we would all have a very merry Xmas. So we can extrapolate all we want and hope for the best but at this time the latest comment by Matt Coffey is 4-500 patients and that is a fact and until we hear different it is what it is. Am hoping for less and of course AA would solve all the problems but until we hear the news telling us so, the latest comments in the podcast are relevant and up to date.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing